{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:21:27Z","timestamp":1760833287992,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.nmd.2020.01.001","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T19:15:04Z","timestamp":1579202104000},"page":"246-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report"],"prefix":"10.1016","volume":"30","author":[{"given":"Giulia","family":"Nicocia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-9460","authenticated-orcid":false,"given":"Antonino","family":"Lupica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rodolico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nmd.2020.01.001_bib0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2020.01.001_bib0002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1586\/1744666X.2015.1047345","article-title":"The role of tregulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics","volume":"11","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.nmd.2020.01.001_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","article-title":"Diagnosis and treatment of psoriatic arthritis","volume":"52","author":"Mease","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.nmd.2020.01.001_bib0004","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11926-014-0414-y","article-title":"The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment","volume":"16","author":"Frleta","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.nmd.2020.01.001_bib0005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.nmd.2020.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.nmd.2020.01.001_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4081\/reumatismo.2016.873","article-title":"New approved drugs for psoriatic arthritis","volume":"68","author":"Perrotta","year":"2016","journal-title":"Reumatismo"},{"issue":"3","key":"10.1016\/j.nmd.2020.01.001_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nmd.2020.01.001_bib0009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"issue":"1\u20132","key":"10.1016\/j.nmd.2020.01.001_bib0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-5728(01)00473-8","article-title":"Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor fc protein","volume":"122","author":"Christadoss","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2020.01.001_bib0011","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1196\/annals.1405.028","article-title":"Etanercept treatment in myasthenia gravis","volume":"1132","author":"Rowin","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.nmd.2020.01.001_bib0012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaut.2005.01.013","article-title":"Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment","volume":"24","author":"T\u00fcz\u00fcn","year":"2005","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.nmd.2020.01.001_bib0013","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.nmd.2020.01.001_bib0014","first-page":"351","article-title":"[A case of myasthenia gravis following sarcoidosis and rheumatoid arthritis]","volume":"53","author":"Sawada","year":"2013","journal-title":"RinshoShinkeigaku"},{"issue":"3","key":"10.1016\/j.nmd.2020.01.001_bib0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/1756-185X.12340","article-title":"Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy?","volume":"18","author":"Bruzzese","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.nmd.2020.01.001_bib0016","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action","volume":"39","author":"Haraoui","year":"2009","journal-title":"Semin Arthritis Rheum"},{"issue":"11\u201312","key":"10.1016\/j.nmd.2020.01.001_bib0017","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new seriesand a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment PharmacolTher"},{"issue":"8","key":"10.1016\/j.nmd.2020.01.001_bib0018","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","article-title":"Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers","volume":"64","author":"Richez","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2020.01.001_bib0019","first-page":"259","article-title":"Immunogenicity assay development and validation for biologic therapy as exemplified by ustekinumab","volume":"196","author":"Mojtahed Poor","year":"2019","journal-title":"ClinExpImmunol"},{"issue":"1","key":"10.1016\/j.nmd.2020.01.001_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1684\/ejd.2016.2888","article-title":"Bullous pemphigoid during ustekinumab therapy in a psoriatic patient","volume":"27","author":"Onsun","year":"2017","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.nmd.2020.01.001_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3315\/jdcr.2010.1041","article-title":"Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy","volume":"4","author":"S\u0142owi\u0144ska","year":"2010","journal-title":"J Dermatol Case Rep"},{"issue":"4","key":"10.1016\/j.nmd.2020.01.001_bib0022","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/j.jaad.2011.11.955","article-title":"Development of linear iga bullous dermatosis in a patient with psoriasis taking ustekinumab","volume":"67","author":"Becker","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nmd.2020.01.001_bib0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fendo.2018.00083","article-title":"Hypophysitis following treatment with ustekinumab: radiological and pathological findings","volume":"9","author":"Ramos-Lev\u00ed","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.nmd.2020.01.001_bib0024","doi-asserted-by":"crossref","first-page":"e32487","DOI":"10.1371\/journal.pone.0032487","article-title":"Population based study of 12 autoimmune diseases in sardinia, italy: prevalence and comorbidity","volume":"7","author":"Sardu","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.nmd.2020.01.001_bib0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0923-2494(97)87239-2","article-title":"The role of tnf alpha and related cytokines in the development and function of the autoreactive T-cell repertoire","volume":"148","author":"Cope","year":"1997","journal-title":"Res Immunol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662030002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089662030002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:35Z","timestamp":1760774975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089662030002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S096089662030002X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.01.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis after etanercept and ustekinumab treatment for psoriatic arthritis: A case report","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}